Abivax【ABVX】銘柄情報

Abivax (ABVX) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

87.85

( 4.65% )

買値

87.55

売値

88.60

出来高

530,615

85.65 日の範囲 93.35

5.12 52 週間の範囲 126.60

時価総額

7.001B

前日終値

83.95

始値

86.50

時刻

87.85

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

186,355 €

発行済株式数

79,694,535

配当利回り

PER

-25.09

1 株当たり利益 (EPS)

-4.52

歳入

4.92M

純利益

-332.2M

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical devel... ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

www.abivax.com

本社

Paris, France

設立

2026

Abivax is listed in the Healthcare sector of the ユーロネクスト with ticker ABVX. The last closing price for Abivax was 83.95 €. Over the last year, Abivax shares have traded in a share price range of 5.12 € to 126.60 €.

Abivax currently has 79,694,535 shares in issue. The market capitalisation of Abivax is 7.00 € billion. Abivax has a price to earnings ratio (PE ratio) of -25.09.

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to...

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a...

Abivax Announces Results of its May 11, 2026 Annual General Meeting

Abivax Announces Results of its May 11, 2026 Annual General Meeting PARIS, France – May 11, 2026 – 10:05 pm...

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares

Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American...

Abivax to Present Data on Obefazimod at Digestive Disease Week®

Abivax to Present Data on Obefazimod at Digestive Disease Week® Presentations Highlight Comprehensive...

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents

Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026Availability of the Preparatory...

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies

Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies Abivax publishes...

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates

Abivax Announces Full Year 2025 Financial Results and Provides Business Updates ABTECT Phase 3 Data Safety...

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026

Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and...

Abivax Provides 2026 Corporate Outlook

Abivax Provides 2026 Corporate Outlook New market insights indicate significant future expansion of the...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-25.15	-22.2566371681	113	118.6	60.45	1601748	94.84588039	DE
4	-20.25	-18.7326549491	108.1	118.6	60.45	518955	97.56765956	DE
12	-13.95	-13.7033398821	101.8	118.6	60.45	335910	100.39316751	DE
26	-6.75	-7.13530655391	94.6	126.6	60.45	239156	101.51702755	DE
52	80.6	1111.72413793	7.25	126.6	5.12	190056	84.7182768	DE
156	69.45	377.445652174	18.4	126.6	4.51	83851	62.08842643	DE
260	59.85	213.75	28	126.6	4.51	61285	52.79477899	DE